Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Delivery of self-amplifying RNA vaccines in in vitro reconstituted virus-like particles.

Biddlecome A, Habte HH, McGrath KM, Sambanthamoorthy S, Wurm M, Sykora MM, Knobler CM, Lorenz IC, Lasaro M, Elbers K, Gelbart WM.

PLoS One. 2019 Jun 4;14(6):e0215031. doi: 10.1371/journal.pone.0215031. eCollection 2019.

2.

Systemic Alanine Glyoxylate Aminotransferase mRNA Improves Glyoxylate Metabolism in a Mouse Model of Primary Hyperoxaluria Type 1.

Kukreja A, Lasaro M, Cobaugh C, Forbes C, Tang JP, Gao X, Martin-Higueras C, Pey AL, Salido E, Sobolov S, Subramanian RR.

Nucleic Acid Ther. 2019 Apr;29(2):104-113. doi: 10.1089/nat.2018.0740. Epub 2019 Jan 24.

PMID:
30676254
3.

Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action.

Sheridan D, Yu ZX, Zhang Y, Patel R, Sun F, Lasaro MA, Bouchard K, Andrien B, Marozsan A, Wang Y, Tamburini P.

PLoS One. 2018 Apr 12;13(4):e0195909. doi: 10.1371/journal.pone.0195909. eCollection 2018.

4.

Quantitative Systems Pharmacology Model of hUGT1A1-modRNA Encoding for the UGT1A1 Enzyme to Treat Crigler-Najjar Syndrome Type 1.

Apgar JF, Tang JP, Singh P, Balasubramanian N, Burke J, Hodges MR, Lasaro MA, Lin L, Miliard BL, Moore K, Jun LS, Sobolov S, Wilkins AK, Gao X.

CPT Pharmacometrics Syst Pharmacol. 2018 Jun;7(6):404-412. doi: 10.1002/psp4.12301. Epub 2018 Apr 26.

5.

Leveraging Rational Protein Engineering to Improve mRNA Therapeutics.

Farelli JD, Asrani KH, Isaacs C, deBear JS, Stahley MR, Shah A, Lasaro MA, Cheng CJ, Subramanian RR.

Nucleic Acid Ther. 2018 Apr;28(2):74-85. doi: 10.1089/nat.2017.0697. Epub 2018 Feb 13.

PMID:
29437538
6.

Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn.

Yang D, Giragossian C, Castellano S, Lasaro M, Xiao H, Saraf H, Hess Kenny C, Rybina I, Huang ZF, Ahlberg J, Bigwarfe T, Myzithras M, Waltz E, Roberts S, Kroe-Barrett R, Singh S.

MAbs. 2017 Oct;9(7):1105-1117. doi: 10.1080/19420862.2017.1359455. Epub 2017 Aug 8.

7.

Efficient Qualitative and Quantitative Determination of Antigen-induced Immune Responses.

Yang D, Frego L, Lasaro M, Truncali K, Kroe-Barrett R, Singh S.

J Biol Chem. 2016 Jul 29;291(31):16361-74. doi: 10.1074/jbc.M116.736660. Epub 2016 Jun 10.

8.

Targeting Complement Pathways During Cold Ischemia and Reperfusion Prevents Delayed Graft Function.

Yu ZX, Qi S, Lasaro MA, Bouchard K, Dow C, Moore K, Wu Z, Barama A, Xu J, Johnson K, Marozsan AJ, Wang Y.

Am J Transplant. 2016 Sep;16(9):2589-97. doi: 10.1111/ajt.13797. Epub 2016 Apr 8.

9.

Efficacy of Targeted Complement Inhibition in Experimental C3 Glomerulopathy.

Ruseva MM, Peng T, Lasaro MA, Bouchard K, Liu-Chen S, Sun F, Yu ZX, Marozsan A, Wang Y, Pickering MC.

J Am Soc Nephrol. 2016 Feb;27(2):405-16. doi: 10.1681/ASN.2014121195. Epub 2015 Jun 5.

10.

Escherichia coli isolate for studying colonization of the mouse intestine and its application to two-component signaling knockouts.

Lasaro M, Liu Z, Bishar R, Kelly K, Chattopadhyay S, Paul S, Sokurenko E, Zhu J, Goulian M.

J Bacteriol. 2014 May;196(9):1723-32. doi: 10.1128/JB.01296-13. Epub 2014 Feb 21.

11.

Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents.

Teixeira LH, Tararam CA, Lasaro MO, Camacho AG, Ersching J, Leal MT, Herrera S, Bruna-Romero O, Soares IS, Nussenzweig RS, Ertl HC, Nussenzweig V, Rodrigues MM.

Infect Immun. 2014 Feb;82(2):793-807. doi: 10.1128/IAI.01410-13. Epub 2013 Dec 9.

12.

Influenza virus specific CD8⁺ T cells exacerbate infection following high dose influenza challenge of aged mice.

Parzych EM, DiMenna LJ, Latimer BP, Small JC, Kannan S, Manson B, Lasaro MO, Wherry EJ, Ertl HC.

Biomed Res Int. 2013;2013:876314. doi: 10.1155/2013/876314. Epub 2013 Sep 26.

13.

Role of complement activation in obliterative bronchiolitis post-lung transplantation.

Suzuki H, Lasbury ME, Fan L, Vittal R, Mickler EA, Benson HL, Shilling R, Wu Q, Weber DJ, Wagner SR, Lasaro M, Devore D, Wang Y, Sandusky GE, Lipking K, Pandya P, Reynolds J, Love R, Wozniak T, Gu H, Brown KM, Wilkes DS.

J Immunol. 2013 Oct 15;191(8):4431-9. doi: 10.4049/jimmunol.1202242. Epub 2013 Sep 16.

14.

Correlates of relative resistance against low-dose rectal simian immunodeficiency virus challenges in peripheral blood mononuclear cells of vaccinated rhesus macaques.

Kurupati R, Tuyishime S, Kossenkov AV, Sazanovich M, Haut LH, Lasaro MO, Ratcliffe SJ, Bosinger SE, Carnathan DG, Lewis M, Showe LC, Silvestri G, Ertl HC.

J Leukoc Biol. 2013 Mar;93(3):437-48. doi: 10.1189/jlb.0612287. Epub 2012 Dec 27.

15.

Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice.

Lasaro MO, Sazanovich M, Giles-Davis W, Mrass P, Bunte RM, Sewell DA, Hussain SF, Fu YX, Weninger W, Paterson Y, Ertl HC.

Mol Ther. 2011 Sep;19(9):1727-36. doi: 10.1038/mt.2011.88. Epub 2011 May 17.

16.

Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primates.

Li H, Lasaro MO, Jia B, Lin SW, Haut LH, High KA, Ertl HC.

Mol Ther. 2011 Nov;19(11):2021-30. doi: 10.1038/mt.2011.81. Epub 2011 May 17.

17.

Vaccination with Ad5 vectors expands Ad5-specific CD8 T cells without altering memory phenotype or functionality.

Hutnick NA, Carnathan DG, Dubey SA, Cox KS, Kierstead L, Makadonas G, Ratcliffe SJ, Lasaro MO, Robertson MN, Casimiro DR, Ertl HC, Betts MR.

PLoS One. 2010 Dec 22;5(12):e14385. doi: 10.1371/journal.pone.0014385.

18.

Vaccine-induced T cells provide partial protection against high-dose rectal SIVmac239 challenge of rhesus macaques.

Lasaro MO, Haut LH, Zhou X, Xiang Z, Zhou D, Li Y, Giles-Davis W, Li H, Engram JC, Dimenna LJ, Bian A, Sazanovich M, Parzych EM, Kurupati R, Small JC, Wu TL, Leskowitz RM, Klatt NR, Brenchley JM, Garber DA, Lewis M, Ratcliffe SJ, Betts MR, Silvestri G, Ertl HC.

Mol Ther. 2011 Feb;19(2):417-26. doi: 10.1038/mt.2010.238. Epub 2010 Nov 16.

19.

A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge.

Zhou D, Wu TL, Lasaro MO, Latimer BP, Parzych EM, Bian A, Li Y, Li H, Erikson J, Xiang Z, Ertl HC.

Mol Ther. 2010 Dec;18(12):2182-9. doi: 10.1038/mt.2010.202. Epub 2010 Sep 28.

20.

Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein D.

Diniz MO, Lasaro MO, Ertl HC, Ferreira LC.

Clin Vaccine Immunol. 2010 Oct;17(10):1576-83. doi: 10.1128/CVI.00264-10. Epub 2010 Aug 25.

21.

Targeting inhibitory pathways in cancer immunotherapy.

Lasaro MO, Ertl HC.

Curr Opin Immunol. 2010 Jun;22(3):385-90. doi: 10.1016/j.coi.2010.04.005. Epub 2010 May 12. Review.

22.

Augmentation of primary influenza A virus-specific CD8+ T cell responses in aged mice through blockade of an immunoinhibitory pathway.

DiMenna L, Latimer B, Parzych E, Haut LH, Töpfer K, Abdulla S, Yu H, Manson B, Giles-Davis W, Zhou D, Lasaro MO, Ertl HC.

J Immunol. 2010 May 15;184(10):5475-84. doi: 10.4049/jimmunol.0903808. Epub 2010 Apr 21.

23.

New insights on adenovirus as vaccine vectors.

Lasaro MO, Ertl HC.

Mol Ther. 2009 Aug;17(8):1333-9. doi: 10.1038/mt.2009.130. Epub 2009 Jun 9. Review.

24.

Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens.

Tatsis N, Lasaro MO, Lin SW, Haut LH, Xiang ZQ, Zhou D, Dimenna L, Li H, Bian A, Abdulla S, Li Y, Giles-Davis W, Engram J, Ratcliffe SJ, Silvestri G, Ertl HC, Betts MR.

J Immunol. 2009 May 15;182(10):6587-99. doi: 10.4049/jimmunol.0900317. Erratum in: J Immunol. 2009 Dec 1;183(11):7611. Haut, Larissa H [added].

25.

Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo.

Pichla-Gollon SL, Lin SW, Hensley SE, Lasaro MO, Herkenhoff-Haut L, Drinker M, Tatsis N, Gao GP, Wilson JM, Ertl HC, Bergelson JM.

J Virol. 2009 Jun;83(11):5567-73. doi: 10.1128/JVI.00405-09. Epub 2009 Mar 11.

26.

Functional and immunological characterization of a natural polymorphic variant of a heat-labile toxin (LT-I) produced by enterotoxigenic Escherichia coli (ETEC).

Lasaro MA, Mathias-Santos C, Rodrigues JF, Ferreira LC.

FEMS Immunol Med Microbiol. 2009 Jan;55(1):93-9. doi: 10.1111/j.1574-695X.2008.00506.x. Epub 2008 Dec 9.

27.

F1C fimbriae play an important role in biofilm formation and intestinal colonization by the Escherichia coli commensal strain Nissle 1917.

Lasaro MA, Salinger N, Zhang J, Wang Y, Zhong Z, Goulian M, Zhu J.

Appl Environ Microbiol. 2009 Jan;75(1):246-51. doi: 10.1128/AEM.01144-08. Epub 2008 Nov 7. Review.

28.
29.

Capsular antigen fraction 1 and Pla modulate the susceptibility of Yersinia pestis to pulmonary antimicrobial peptides such as cathelicidin.

Galván EM, Lasaro MA, Schifferli DM.

Infect Immun. 2008 Apr;76(4):1456-64. doi: 10.1128/IAI.01197-07. Epub 2008 Jan 28.

30.

Genetic diversity of heat-labile toxin expressed by enterotoxigenic Escherichia coli strains isolated from humans.

Lasaro MA, Rodrigues JF, Mathias-Santos C, Guth BE, Balan A, Sbrogio-Almeida ME, Ferreira LC.

J Bacteriol. 2008 Apr;190(7):2400-10. doi: 10.1128/JB.00988-07. Epub 2008 Jan 25.

31.

Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses.

Lasaro MO, Tatsis N, Hensley SE, Whitbeck JC, Lin SW, Rux JJ, Wherry EJ, Cohen GH, Eisenberg RJ, Ertl HC.

Nat Med. 2008 Feb;14(2):205-12. doi: 10.1038/nm1704. Epub 2008 Jan 13.

32.

Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice.

Lin SW, Hensley SE, Tatsis N, Lasaro MO, Ertl HC.

J Clin Invest. 2007 Dec;117(12):3958-70.

33.

Adjuvant requirement for successful immunization with recombinant derivatives of Plasmodium vivax merozoite surface protein-1 delivered via the intranasal route.

Bargieri DY, Rosa DS, Lasaro MA, Ferreira LC, Soares IS, Rodrigues MM.

Mem Inst Oswaldo Cruz. 2007 Jun;102(3):313-7.

34.

Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors.

McCoy K, Tatsis N, Korioth-Schmitz B, Lasaro MO, Hensley SE, Lin SW, Li Y, Giles-Davis W, Cun A, Zhou D, Xiang Z, Letvin NL, Ertl HC.

J Virol. 2007 Jun;81(12):6594-604. Epub 2007 Apr 11.

35.

Adhesin-dependent binding and uptake of Salmonella enterica serovar Typhimurium by dendritic cells.

Guo A, Lasaro MA, Sirard JC, Kraehenbühl JP, Schifferli DM.

Microbiology. 2007 Apr;153(Pt 4):1059-69.

PMID:
17379714
36.

Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.

Li H, Murphy SL, Giles-Davis W, Edmonson S, Xiang Z, Li Y, Lasaro MO, High KA, Ertl HC.

Mol Ther. 2007 Apr;15(4):792-800. Epub 2007 Jan 23.

37.

Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector.

Hensley SE, Cun AS, Giles-Davis W, Li Y, Xiang Z, Lasaro MO, Williams BR, Silverman RH, Ertl HC.

Mol Ther. 2007 Feb;15(2):393-403.

38.

A CD46-binding chimpanzee adenovirus vector as a vaccine carrier.

Tatsis N, Blejer A, Lasaro MO, Hensley SE, Cun A, Tesema L, Li Y, Gao GP, Xiang ZQ, Zhou D, Wilson JM, Ertl HC.

Mol Ther. 2007 Mar;15(3):608-17. Epub 2007 Jan 16.

39.

Random migration precedes stable target cell interactions of tumor-infiltrating T cells.

Mrass P, Takano H, Ng LG, Daxini S, Lasaro MO, Iparraguirre A, Cavanagh LL, von Andrian UH, Ertl HC, Haydon PG, Weninger W.

J Exp Med. 2006 Nov 27;203(12):2749-61. Epub 2006 Nov 20.

40.
41.

Production and release of heat-labile toxin by wild-type human-derived enterotoxigenic Escherichia coli.

Lasaro MA, Rodrigues JF, Mathias-Santos C, Guth BE, Régua-Mangia A, Piantino Ferreira AJ, Takagi M, Cabrera-Crespo J, Sbrogio-Almeida ME, de Souza Ferreira LC.

FEMS Immunol Med Microbiol. 2006 Oct;48(1):123-31.

42.

Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1.

Lasaro MO, Diniz MO, Reyes-Sandoval A, Ertl HC, Ferreira LC.

Microbes Infect. 2005 Dec;7(15):1541-50. Epub 2005 Sep 9.

PMID:
16213178
43.

Prime-boost vaccine regimen confers protective immunity to human-derived enterotoxigenic Escherichia coli.

Lasaro MO, Luiz WB, Sbrogio-Almeida ME, Ferreira LC.

Vaccine. 2005 Mar 31;23(19):2430-8.

PMID:
15752829
45.

Antibody-inducing properties of a prototype bivalent herpes simplex virus/enterotoxigenic Escherichia coli DNA vaccine.

Lásaro MO, Alves AM, Botosso VF, Durigon EL, Ferreira LC.

FEMS Immunol Med Microbiol. 2003 Jan 21;35(1):25-31.

46.

DNA immunisation against the CFA/I fimbriae of enterotoxigenic Escherichia coli (ETEC).

Alves AM, Lásaro MO, Almeida DF, Ferreira LC.

Vaccine. 2000 Nov 22;19(7-8):788-95.

PMID:
11115700
48.

New vaccine strategies against enterotoxigenic Escherichia coli. I: DNA vaccines against the CFA/I fimbrial adhesin.

Alves AM, Lásaro MO, Almeida DF, Ferreira LC.

Braz J Med Biol Res. 1999 Feb;32(2):223-9. Review.

PMID:
10347758
49.

Antibody response in mice immunized with a plasmid DNA encoding the colonization factor antigen I of enterotoxigenic Escherichia coli.

Alves AM, Lásaro MO, Pyrrho AS, Gattass CR, de Almeida DF, Ferreira LC.

FEMS Immunol Med Microbiol. 1999 Apr;23(4):321-30.

50.

Supplemental Content

Loading ...
Support Center